Meeting
2016 Genitourinary Cancers Symposium
Molecular tumor grading of non muscle invasive bladder cancer based on whole transcriptome analysis.
Authors
Jess Shen
Lunenfeld Tanenbaum Research Insitute, Toronto, ON, Canada
Jess Shen , Aidan Noon , Yu LIU , Cynthia Kuk , C Ilczynski , R Ni , B Sukhu , K Chan , Adrian Gunaratne , Annette Erlich , Chris Cremer , Quaid Morris , Nuno L Barbosa-Morais , Neil Eric Fleshner , Girish S. Kulkarni , Ben Blencowe , Azar Azad , Theodorus van der Kwast , Alexandre Zlotta , Jeff L Wrana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 467)
DOI
10.1200/jco.2016.34.2_suppl.467
Abstract #
467
Poster Bd #
K16
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC).
First Author: Jaleh Fallah
Poster
2018 Genitourinary Cancers Symposium
Evaluation of a 29 gene classifier for basal/non basal prediction in muscle-invasive bladder cancer FFPE samples.
First Author: Yves Allory
Poster
2024 ASCO Annual Meeting
Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.
First Author: İlayda Hasakioğulları
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Shilpa Gupta